We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-8.37%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.28B
AUM Growth
-$1.41B
Cap. Flow
-$1.19B
Cap. Flow %
-22.61%
Top 10 Hldgs %
53.54%
Holding
466
New
23
Increased
24
Reduced
24
Closed
360

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$72.5M
2
LEGN icon
Legend Biotech
LEGN
+$64.3M
3
OSCR icon
Oscar Health
OSCR
+$64.1M
4
DVAX
Dynavax Technologies
DVAX
+$62.6M
5
INDV icon
Indivior Pharmaceuticals
INDV
+$39M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$187M
2
KURA icon
Kura Oncology
KURA
+$106M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$66.5M
4
SGRY icon
Surgery Partners
SGRY
+$57.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$56.2M

Sector Composition

Rank Sector Weight
1 Healthcare 87.97%
2 Industrials 0.23%
3 Consumer Staples 0.01%
4 Energy 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNMD icon
26
CONMED
CNMD
$1.31B
$41.9M 0.79%
611,964
-2,926
-0.5% -$204K
CGEM icon
27
Cullinan Oncology
CGEM
$1.08B
$41.2M 0.78%
3,379,399
+99,399
+3% +$1.43M
EHAB
28
DELISTED
Enhabit
EHAB
$39.1M 0.74%
5,010,972
+13,226
+0.3% +$101K
LKFT
29
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.91B
$38.8M 0.73%
1,411,000
– –
PHVS icon
30
Pharvaris
PHVS
$2.41B
$38.7M 0.73%
2,017,464
-14,236
-0.7% -$293K
IRON icon
31
Disc Medicine
IRON
$2.87B
$38.1M 0.72%
600,515
-422,750
-41% -$24.5M
ALNY icon
32
Alnylam Pharmaceuticals
ALNY
$36.4B
$34.2M 0.65%
145,191
+191
+0.1% +$50.2K
DAWN
33
DELISTED
Day One Biopharmaceuticals
DAWN
$32.9M 0.62%
2,596,033
-21,680
-0.8% -$302K
PHR icon
34
Phreesia
PHR
$657M
$32M 0.61%
1,271,832
+727,384
+134% +$15.5M
BCAX
35
Bicara Therapeutics
BCAX
$1.81B
$31.3M 0.59%
1,795,174
– –
DCGO icon
36
DocGo
DCGO
$66.7M
$30.5M 0.58%
7,195,956
-1,870,182
-21% -$7.21M
INMD icon
37
InMode
INMD
$889M
$26.4M 0.5%
1,578,708
– –
SVRA icon
38
Savara
SVRA
$1.12B
$24.4M 0.46%
7,964,000
+1,498,223
+23% +$5.22M
CGON icon
39
CG Oncology
CGON
$6.29B
$24.4M 0.46%
851,593
+898
+0.1% +$30.7K
KYMR icon
40
Kymera Therapeutics
KYMR
$9.41B
$23.9M 0.45%
+593,000
New +$26.8M
MREO
41
Mereo BioPharma
MREO
$49.1M
$23.5M 0.44%
6,710,429
– –
ESTA icon
42
PUT
Establishment Labs
ESTA
$2.76B
$23M 0.44%
+500,000
New +$21.8M
TXG icon
43
10x Genomics
TXG
$5.45B
$21.5M 0.41%
1,497,000
-11,943
-0.8% -$188K
LNTH icon
44
Lantheus
LNTH
$6.93B
$21.5M 0.41%
240,218
– –
COGT icon
45
Cogent Biosciences
COGT
$6.62B
$20.5M 0.39%
2,631,000
-1,113,263
-30% -$11.1M
SEPN
46
Septerna Inc
SEPN
$1.49B
$19.7M 0.37%
+861,814
New +$20.4M
NVST icon
47
Envista
NVST
$4.34B
$19.6M 0.37%
1,018,415
+998,248
+4,950% +$19.7M
PCVX icon
48
Vaxcyte
PCVX
$8.02B
$18.4M 0.35%
225,000
– –
RXRX icon
49
Recursion Pharmaceuticals
RXRX
$1.56B
$15.6M 0.3%
2,315,000
– –
FHTX icon
50
Foghorn Therapeutics
FHTX
$308M
$15.4M 0.29%
3,255,514
+227,628
+8% +$1.66M
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2024 Portfolio in Review

As of Q4 2024, Deerfield Management held 466 positions worth $5.28B, down 21% from $6.69B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $1.19B in Q4 2024, closing 360 positions and reducing 24 holdings. Its most notable exit was Kura Oncology, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Deerfield Management opened a new position in Legend Biotech worth $50.5M.

  • Deerfield Management's largest Q4 2024 buy was Legend Biotech: 1,551,718 shares worth $50.5M.
  • Deerfield Management added most to NewAmsterdam Pharma in Q4 2024, an estimated $72.5M increase.
  • Deerfield Management's biggest Q4 2024 reduction was Nuvalent, cutting an estimated $187M.
  • Deerfield Management fully exited Kura Oncology in Q4 2024, selling an estimated $106M.
  • Deerfield Management's ten largest holdings make up 54% of its $5.28B portfolio in Q4 2024.
  • Deerfield Management opened 23 new positions and closed 360 in Q4 2024.
  • Deerfield Management's portfolio value fell 21% quarter-over-quarter to $5.28B.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.